Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron

Dozens of states sue to block the sale of 23andMe’s genetic data after its former CEO pushes the purchase price $50 million higher

The possible sale of 23andMe’s genetic data could set a precedent for future cases where companies look to offload increasingly personal data.

Fortune

States Challenge 23andMe Over Genetic Data Sale in Bankruptcy Deal

States sue to halt Regeneron's 23andMe acquisition, citing privacy concerns over user DNA data, as a court-ordered report on the deal's impact looms.

International Business Times

23andMe back on the auction block after former CEO makes 11th-hour bid

Anne Wojcicki, ex-CEO of the DNA testing firm, put in a $305m bid, upending Regeneron’s $256m agreement

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

The New Twist In Regeneron's 23andMe Bankruptcy Buyout

23andMe wants to reopen bidding on its assets after former CEO Anne Wojcicki put together a $305 million offer, topping Regeneron.

Investors Business Daily

Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure

Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.

Investors Business Daily

Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Despite Regeneron Pharmaceuticals' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

Barchart

23andMe Sells DNA Database to Regeneron in £256m Deal: Is Your Data Safe?

23andMe's sale to Regeneron transfers genetic data for drug development, raising privacy issues and concerns over consumer control and benefits.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Trump the AI salesman makes deals in the Gulf – and rich men benefit

The president sold the US model of the industry that made it: enormous power concentrated in the hands of a few men

The Guardian - US

Bankrupt DNA testing firm 23andMe to be purchased for $256m

Drugmaker Regeneron Pharmaceuticals’ capture of genetic testing firm in bankruptcy auction raises privacy concerns

The Guardian - US

Biotechnology company Regeneron buying 23andMe for $256 million

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection

The Independent UK

23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction

Regeneron Pharmaceuticals said Monday it will acquire substantially all of DNA-testing outfit 23andMe for $256 million after coming out on top at a bankruptcy auction.

Investors Business Daily

Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025

CCOI, AESI, and REGN are near one-year lows but remain favored by analysts; watch these stocks for future growth potential.

MarketBeat

Best Biotech Stocks to Buy in 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

MarketBeat

Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down

Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

3 Stocks With Ironclad Balance Sheets for Long-Term Stability

Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market.

MarketBeat

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

Barchart

Regeneron Pharmaceuticals Stock: Analyst Estimates & Ratings

Despite Regeneron Pharmaceuticals’ underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

MarketBeat

Billions in Buybacks: 4 Stocks Rewarding Shareholders Now

These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

Fortune

Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers

The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and more.

Investors Business Daily

Regeneron Culls Losses After High-Dose Eylea Sales Disappoint

Regeneron stock recovered Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea.

Investors Business Daily

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Barchart

3 S&P 500 Stocks to Buy in 2025 With Big Rebound Potential

As markets rise, a handful of resilient stocks that were bruised could rebound over 30%, powered by strong fundamentals and bullish prospects.

Barchart

3 Nasdaq-100 Stocks With 25% to 53% Upside Potential

These three Nasdaq-100 Stocks shine as prime opportunities as analysts forecast 25% to 53% upside potential.

Barchart

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Despite Regeneron Pharmaceuticals’ significant underperformance relative to Nasdaq recently, Wall Street analysts remain strongly optimistic about the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.